New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 13, 2013
11:55 EDTAZN, EZCH, ARRS, SNTA, JNYHigh option volume stocks: SNTA EZCH JNY ARRS AZN
News For SNTA;EZCH;JNY;ARRS;AZN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 30, 2015
09:10 EDTAZNAstraZeneca CEO: Acquisition purchasing prices 'pretty hefty,' Reuters reports
Subscribe for More Information
07:25 EDTAZNCharles River, AstraZeneca renew strategic partnership agreement
Charles River Laboratories International (CRL) announced that it has extended its initial three-year partnership with AstraZeneca (AZN) for an additional five-year period. Under the agreement, which extends into 2020, Charles River retains its position as AstraZeneca’s preferred strategic partner for outsourced regulated safety assessment and development DMPK.
05:57 EDTAZNRoche submits filing to FDA for companion diagnostic for NSCLC drug therapy
Roche announced it has submitted the cobas EGFR Mutation Test v2 for Premarket Approval, or PMA, to the FDA, as a companion diagnostic test for AZD9291, an AstraZeneca (AZN) investigational therapy for non-small cell lung cancer patients with an acquired resistant mutation. Patients with non-small cell lung cancer who have adenocarcinoma with tumor containing an EGFR sensitizing mutation show significant benefit from currently available EGFR TKI therapies. However, approximately two-thirds of these patients will relapse and develop drug resistance. In many cases, this resistance is caused by an acquired mutation called T790M. The cobas EGFR v2 test can aid clinicians to appropriately select NSCLC patients who have acquired the T790M mutation and are most likely to benefit from AstraZeneca's novel therapy.
July 29, 2015
16:25 EDTARRSARRIS sees Q3 adjusted EPS 52c-58c, consensus 64c
Sees Q3 revenue $1.21B-$1.26B, consensus $1.3B. Sees closing Pace acquisition in Q4.
16:23 EDTARRSARRIS sees Q2 adjusted EPS 53c, consensus 53c
Sees Q2 revenue $1.26B, consensus $1.26B. Sees book-to-bill ratio 0.94. "As we have highlighted, we are encountering headwinds which we expect to continue through 2015, in particular those related to industry consolidations and the strong US dollar," said the company.
July 28, 2015
13:43 EDTARRSEarnings Watch: Akamai reports as cloud services, content streaming accelerate
Subscribe for More Information
07:20 EDTAZNBrookings Institute to hold a public meeting
Subscribe for More Information
July 27, 2015
05:25 EDTAZNGenzyme acquires Caprelsa from AstraZeneca for $300M
Genzyme, a Sanofi (SNY) company, announced that it has entered into a definitive agreement with AstraZeneca (AZN) to acquire Caprelsa, a rare disease therapy, indicated for the treatment of symptomatic or progressive medullary thyroid carcinoma in patients with unresectable locally advanced or metastatic disease. Caprelsa is an oral kinase inhibitor treatment and is currently available in 28 countries. Caprelsa is in Phase III development for differentiated thyroid carcinoma, with the study expected to finish in the second half of 2015. Under the terms of the agreement, Genzyme will pay AstraZeneca up to $300M, including an upfront payment of $165M to acquire the global rights to sell and further develop Caprelsa, and further development and sales milestone payments of up to $135M. The transaction does not include the transfer of any AstraZeneca employees or facilities.
July 23, 2015
10:00 EDTARRSOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: ARRIS (ARRS) initiated with a Buy at Drexel Hamilton... AVG Technologies (AVG) initiated with an Overweight at JPMorgan... Aaron's (AAN) initiated with a Hold at Cantor... Aimco (AIV) initiated with a Hold at Canaccord... American Campus (ACC) initiated with a Hold at Canaccord... Antero Midstream (AM) initiated with a Buy at DA Davidson... Cheniere Energy Partners LP (CQP) initiated with a Buy at DA Davidson... CommScope (COMM) initiated with a Buy at Drexel Hamilton... Digirad Corp (DRAD) initiated with a Buy at B. Riley... Dominion Midstream (DM) initiated with a Buy at DA Davidson... Education Realty (EDR) initiated with a Buy at Canaccord... Enterprise Products (EPD) initiated with a Buy at DA Davidson... Essex Property Trust (ESS) initiated with a Hold at Canaccord... Extra Space Storage (EXR) initiated with an Outperform at Baird... Harmonic (HLIT) initiated with a Hold at Drexel Hamilton... Imprimis (IMMY) initiated with a Buy at Sterne Agee CRT... National Retail Properties (NNN) initiated with a Neutral at DA Davidson... Nutrisystem (NTRI) initiated with a Buy at Lake Street... PLC Systems Inc (PLC) initiated with a Buy at Sterne Agee CRT... PayPal (PYPL) initiated with a Neutral at UBS... Preferred Apartment (APTS) initiated with a Buy at Canaccord... Public Storage (PSA) initiated with a Neutral at Baird... Realty Income (O) initiated with a Neutral at DA Davidson... RingCentral (RNG) initiated with an Overweight at JPMorgan... SeaChange (SEAC) initiated with a Hold at Drexel Hamilton... Sovran Self Storage (SSS) initiated with an Outperform at Baird... Spectra Energy Partners (SEP) initiated with a Buy at DA Davidson... U-Store It Trust (YSI) initiated with an Outperform at Baird... Whitestone REIT (WSR) initiated with an Outperform at Baird... eBay (EBAY) initiated with an Equal Weight at Morgan Stanley.
09:37 EDTARRSARRIS initiated with a Buy at Drexel Hamilton
July 22, 2015
13:58 EDTAZNPiper cuts Array target by only 50c after failed trial
Piper Jaffray analyst Edward Tenthoff says selumetinib for Uveal Melanoma is a small indication and represented only a small part of his valuation for Array BioPharma (ARRY). As such, after partner AstraZeneca (AZN) announced that selumetinib failed in the Phase III trial, the analyst cut his price target for Array by only 50c to $14.50. The primary drivers for Array remain binimetinib and encorafenib in NRAS and BRAF melanoma and low-grade serous ovarian cancer, the analyst tells investors in a research note. He keeps an Overweight rating on the stock.
09:07 EDTAZNOn The Fly: Pre-market Movers
Subscribe for More Information
05:12 EDTAZNAstraZeneca says Phase 3 study of selumetinib did not meet primary endpoint
AstraZeneca (AZN) announced that the Phase 3 SUMIT study of selumetinib in combination with dacarbazine for the treatment of patients with metastatic uveal melanoma did not meet its primary endpoint of progression free survival. This combination therapy showed an adverse event profile generally consistent with current knowledge of the safety profiles of dacarbazine and selumetinib. A full evaluation of the data is ongoing. Selumetinib is a MEK inhibitor in late-stage development, with a primary Phase 3 program in second-line KRAS-mutant advanced non-small cell lung cancer in combination with docetaxel. Selumetinib is also being investigated in a Phase 3 study in differentiated thyroid cancer and in a Phase 2 registration study in patients with neurofibromatosis Type 1. Selumetinib is an oral small molecule MEK inhibitor invented by Array BioPharma (ARRY) and licensed to AstraZeneca in 2003.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use